First, NASH therapy should aim to eliminate the factors contributing to disease development and progression, reduce hepatocyte damage, prevent steatohepatitis progression to fibrosis and cirrhosis, improve tissue sensitivity to insulin, and manage NASH-related metabolic disorders [4, 5, 26, 27]. This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.